(NASDAQ:UPXI), TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) — Upexi, Inc. (NASDAQ: UPXI) (the “Company” or “Upexi”), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the first quarter 2026 ended September 30, 2025, on Tuesday, November […]

LM Funding Announces Third Quarter 2025 Earnings Call for November 14, 2025 GlobeNewswire November 06, 2025 TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin treasury and mining company, today announced that it has scheduled its third quarter 2025 earnings conference call and

Workhorse Group Reminds Shareholders to Vote Today FOR All Proposals GlobeNewswire November 06, 2025 CINCINNATI, Nov. 06, 2025 (GLOBE NEWSWIRE) — Workhorse Group, Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today mailed a letter to shareholders reminding them to vote today FOR

(NasdaqGM:NKLR), NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (“Terra Innovatum” or the “Company“) (NASDAQ: NKLR), a developer of micro-modular nuclear reactors, announced it will release its third quarter fiscal year 2025 financial results before the opening of financial markets on Monday, November 17, 2025. The Company will conduct a conference

Locafy Reports Strong Commercial Momentum Going into CY 2026 GlobeNewswire November 06, 2025 A$156k in monthly subscription sales added in two months Localizer delivering both strong SEO and AEO results for local businesses Advanced AEO analytics solution to be deployed by end of CY 2025 PERTH, Australia, Nov. 06, 2025 (GLOBE NEWSWIRE) — Locafy Limited

(NasdaqGM:URGN), Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial ZUSDURI received unique J-Code (J9282) in October 2025, effective January 1, 2026 ZUSDURI achieved net product revenue of $1.8

RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights GlobeNewswire November 06, 2025 – Initiated prestIgE Phase 2b trial of ozureprubart in food allergy – Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab

LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) — Evotrex, a California-based company transforming the future of outdoor adventure through bold innovation, today announced its emergence from stealth mode with $16 million in Pre-A funding. The company is transforming what it means to live and travel off-grid by going beyond electric and into a new era

Healthcare Minus the Headache: RokketMed, A Solution to Finding the Care That Counts Turnkey San Francisco Platform Aims to Help All Employers and Workers GlobeNewswire November 06, 2025 SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) — In the face of mounting healthcare compliance complexity and an urgent need for accessible healthcare, San Francisco employers and

(NASDAQ:IOTR), Singapore, Nov. 06, 2025 (GLOBE NEWSWIRE) — iOThree Limited (Nasdaq: IOTR, the “Company”), today announced that the shareholders and the board of directors of the Company approved a one-for-ten reverse share split of the Company's issued and unissued ordinary shares (the “Ordinary Shares”), class A shares, and preferred shares. Beginning November 10, 2025, the